Dr. Meng Ning | Biochemistry, Genetics and Molecular Biology | Best Researcher Award
Chiba University | China
Dr. Meng Ning is an accomplished researcher at Chiba University, Japan, recognized for her pioneering work in the epigenetic regulation of cancer. She has made substantial contributions to understanding the non-catalytic roles of chromatin regulators, particularly in gastric cancer. Her expertise bridges molecular biology and clinical gastrointestinal oncology, enabling her to translate laboratory discoveries into potential therapeutic strategies. Meng Ning is known for her meticulous experimental design, innovative application of genome-editing technologies, and dedication to advancing cancer research through both independent studies and collaborative projects.
Professional Profile
ORCID
Education
Dr. Meng Ning completed her doctoral studies at Chiba University, Japan, where she focused on elucidating novel mechanisms of cancer progression. Her Ph.D. research revealed a previously unrecognized non-catalytic function of SETD1A in gastric cancer via the E2F4–TAF6 axis. Employing advanced techniques including transcriptomics, epigenomics, and genome-editing approaches, she was able to demonstrate this mechanism independently of traditional methyltransferase activity. Her academic training combines rigorous laboratory research with a strong foundation in clinical oncology, preparing her to conduct translational studies that link fundamental discoveries with therapeutic potential.
Experience
Dr. Meng Ning has extensive experience in both experimental and translational cancer research. She has collaborated with the Department of Pathology at the University of Tokyo to analyze clinical gastric cancer specimens, integrating molecular findings with patient data. Her work spans NGS-based studies, CRISPR genome editing, and multi-omics analyses, reflecting a versatile approach to cancer biology. Beyond laboratory research, she has contributed to the mentorship of junior researchers, participated in collaborative projects across institutions, and actively engaged in the scientific community through professional society memberships and research networks.
Research Interests
Dr. Meng Ning’s primary research interest lies in the epigenetic regulation of cancer, with a focus on non-catalytic functions of chromatin regulators. She investigates how these regulators influence tumor proliferation, cellular signaling, and transcriptional networks using advanced molecular biology techniques. Her research integrates next-generation sequencing, genome editing, and integrative bioinformatics to identify novel mechanisms underlying cancer progression. By connecting these molecular insights with clinical oncology, she aims to identify potential therapeutic targets and contribute to the development of innovative cancer treatments.
Awards
Dr. Meng Ning is nominated for the Best Researcher Award in recognition of her outstanding contributions to cancer epigenetics and translational oncology. Her research has introduced novel concepts in understanding chromatin regulator function and tumor biology, demonstrating originality, technical excellence, and significant impact in the field. Her dedication to advancing cancer research through rigorous experimentation and collaborative endeavors positions her as a leading researcher in her discipline.
Publications
Dr. Meng Ning has authored several high-impact, SCI-indexed publications as first or contributing author. Her work demonstrates innovative methodologies and deep insights into the molecular mechanisms of cancer:
Title: Non-catalytic role of SETD1A promotes gastric cancer cell proliferation through the E2F4–TAF6 axis in the cell cycle
Journal: Cell Death & Disease
Published on: 2025-08-23
Title: Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K
Journal: Breast Cancer Research
Published on: 2025-08-11
Title: Integrated enhancer regulatory network by enhancer–promoter looping in gastric cancer
Journal: NAR Cancer
Published on: 2024-04-08
Conclusion
Dr. Meng Ning exemplifies excellence in scientific research through her innovative studies in cancer epigenetics and her commitment to translational application. Her work bridges basic molecular discoveries and clinical oncology, offering new avenues for therapeutic development. With a combination of technical skill, collaborative engagement, and visionary research, Meng Ning stands out as a highly deserving candidate for the Best Researcher Award. Her contributions not only advance the understanding of cancer biology but also inspire ongoing innovation in epigenetic and translational research.
